Endo pharmaceuticals USA has joined hands with India’s contract research services firm Syngene to develop a novel biological therapeutic molecules against cancer.
Endo will keep all rights to the molecules developed under the collaboration as per the agreement. While syngene international will receive research fees, milestone payments and success fees from Endo.
Endo markets its branded pharmaceuticals products in pain management, urology, endocrinology, oncology,neurology,surgery and primary care.
Syngene is the contract research subsidiary of India’s leading biotherapeutics firm Biocon.
Biocon announced on September 12 that it had inked an exclusive co-development and marketing pact with California-based Amylin Pharmaceuticals for peptide therapeutics. Specifically, this will be geared towards a peptide hybrid or “phybrid” which will combine the properties of two peptides into one small molecule to treat diabetes.
Amylin Pharmaceuticals has been a front-runner in the field of peptide therapeutics and is a leader in the diabetes market. Biocon will bring its recombinant DNA technology, large-scale manufacturing and low-cost pre-clinical and clinical development capabilities to this partnership.
Biocon and Amylin will share the development costs, a significant portion of which will arise in the phase III trials. Even as Amylin will own the intellectual property (IP) rights to the molecule and the “phybrid” technology, Biocon will hold the IP for the manufacturing.
Established in 1978, Biocon Limited is India’s largest biotechnology company by revenue. Promoted by Ms Kiran Mazumdar-Shaw, Biocon has a strategic focus on biopharmaceuticals and research services.
Biocon’s value chain spans discovery, development and commercialization of novel therapeutics. Biocon with initiatives in clinical development, bio-processing and global marketing, delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMEA acceptance. Biocon’s robust product offering includes the world’s first recombinant human insulin, Insugen and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR.
Proprietary technologies and superior knowledge-driven concepts propel our reputation as a ‘full-service research hub’. Leveraging India’s powerful value advantage while continuing to deliver high levels of innovation, we remain compelling collaborators for advanced, cost-effective custom research services.
Endo pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic priscription pharmaceuticals used to treat and manage pain ,bladder cancer, prostate cancer and the early onset of puberty in children, or central precocioius puberty (CPP).